Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Michael B StreiffBjorn HolmstromDana AngeliniAneel AshraniTyler BucknerRobert DiepKleber Yotsumoto FertrinAnnemarie E FogertyNicolas Gallastegui CrestaniRadhika GangarajuCristhiam Rojas-HernandezSamuel Z GoldhaberIbrahim IbrahimTimothy KubalAndrew D LeavittMing LimJanelle MannSimon ManthaColleen MortonAlex NesterAndrew O'BrienThomas L OrtelAlexander PineAllyson PishkoMona RanadeAmirali SalmasiJordan SchaeferEliot WilliamsGeoffrey WoolTheodore WunSarah MontgomeryJamie NguyenDeborah Freedman-CassBailee SlikerPublished in: Journal of the National Comprehensive Cancer Network : JNCCN (2024)
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.